Hint mode is switched on Switch off
For swift navigation between sections

Opus Genetics
LEI 529900C85NBMQFSETD92

PDF download

Choose all Reset all
Download Cancel
Organization name
Opus Genetics, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Opus Genetics, Inc. is a clinical stage biopharmaceutical company dedicated to developing innovative therapeutics for the treatment of cancer.

Awards

News

21/04/2026 Opus Genetics: Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant
02/04/2026 Opus Genetics: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Regulation Fd Disclosure, Financial Statements And Exhibits
01/04/2026 Opus Genetics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Financial Statements And Exhibits
13/02/2026 Opus Genetics: Entry Into A Material Definitive Agreement, Results Of Operations And Financial Condition, Unregistered Sales Of Equity Securities, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Other Events, Financial Statements And Exhibits
05/11/2025 Opus Genetics: Entry Into A Material Definitive Agreement, Other Events, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
II q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    529900C85NBMQFSETD92
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001228627
  • EIN
    11-3516358
Registration is required to get access.